Contemporary Management of Meningiomas with Radiosurgery

Selcuk Demiral, Ferrat Dincoglan, Omer Sager*, Bora Uysal, Hakan Gamsiz, Fatih Ozcan, Bahar Dirican and Murat Beyzadeoglu

Department of Radiation Oncology, University of Health Sciences, Gulhane Medical Faculty, Ankara, Turkey

*Corresponding author: Omer Sager, MD, Associate Professor, Department of Radiation Oncology, University of Health Sciences, Gulhane Medical Faculty, Gn.Tevfik Saglam Cad. 06018, Etlik, Kecioren, Ankara/Turkey, Tel: +90-312-304-4683, Fax: +90-312-304-4680

Abstract
Meningiomas are the most common intracranial benign tumors. While an indolent natural history is typical for benign meningiomas, a wide spectrum of symptoms may occur depending on lesion location and proximity to critical neurovascular structures. A multidisciplinary approach may be warranted for optimal management of meningiomas. In the scarcity of prospective, randomized controlled studies to dictate treatment algorithms, decision making for treatment is based primarily on mostly retrospective data. Surgery plays a central role for meningioma management, however, lesions located at eloquent brain regions in vicinity of critical neurovascular structures may not be amenable to complete surgical removal due to excessive risk of complications. In this context, radiation therapy offers a viable complementary or definitive treatment modality for management of selected patients with meningiomas. Radiosurgery has emerged as a sophisticated form of radiation therapy allowing precisely focused radiation beams to be delivered to well-defined targets under stereotactic localization and image guidance. There is growing body of evidence substantiating the role of radiosurgery in the form of stereotactic radiosurgery (SRS) or fractionated stereotactic radiotherapy (FSRT) for management of meningiomas. Herein, we review the utility of radiosurgery for meningiomas in light of the literature.

Keywords
Meningioma, Radiosurgery, Stereotactic radiosurgery (SRS), Fractionated stereotactic radiotherapy (FSRT)

Introduction
Meningiomas are the most common intracranial benign tumors accounting for approximately one third of all diagnosed intracranial neoplasms [1-9]. These durotic-based tumors are thought to originate from arachnoid cap or meningothelial cells which are present in the arachnoid layer of the meninges [10,11]. Age of presentation is mostly in the 6th to 8th decades of life with the incidence increasing with age [4,5]. Histologically, meningiomas are classified as benign, atypical, or anaplastic (malignant) as per the World Health Organization (WHO) classification scheme with WHO grade I benign meningiomas being the most common type [5,6,11]. According to WHO classification, histological subtypes of WHO grade I meningioma include meningothelial (syncytial) meningioma, psammomatous meningioma, fibroblastic (fibrous) meningioma, transitional (mixed) meningioma, angiomatous (vascular) meningioma, secretory meningioma, lymphoplasmacyte-rich meningioma, metaplastic meningioma, and microcystic meningioma [12]. Histological subtypes of WHO grade II meningioma include chordoid meningioma, clear cell meningioma, and atypical meningioma [12]. Histological subtypes of WHO grade III meningioma include anaplastic (malignant) meningioma, papillary meningioma, and rhabdoid meningioma [12]. Most commonly seen histopathological types in decreasing order include meningothelial meningiomas, fibroblastic meningiomas, transitional meningiomas, psammomatous meningiomas, and other types [12].

Meningiomas may occur in various locations within the central nervous system (CNS). Most common location is the supratentorial region, followed by the base of skull and posterior fossa [12]. Meningiomas located at the supratentorial region include parasagittal meningiomas, convexity meningiomas, parafalcine meningiomas, and intraventricular meningiomas. Meningiomas located at the base of skull include sphenoid ridge meningiomas, olfactory...
groove meningiomas, tuberculum sellae meningiomas, petroclival meningiomas, intraorbital meningiomas, and cavernous sinus meningiomas. Meningiomas located at the posterior fossa include cerebellopontine angle meningiomas, cerebellar convexity meningiomas, foramen magnum meningiomas, peritocular meningiomas, and jugular foramen meningiomas [12].

While benign meningiomas typically follow an indolent course as a slowly growing tumor, few patients with atypical or anaplastic meningiomas may suffer from invasive and recurrent disease occasionally accompanied by distant metastases [13-21].

Magnetic resonance imaging (MRI) is the principal imaging modality for meningiomas. However, imaging with computed tomography (CT) may help detecting tumoral calcifications, hyperostosis of the neighboring bone, and intraosseous growth of the tumor particularly for base of skull lesions [22]. MRI is useful for identification of the dural tail, if present, as post-contrast linear thickening of duramater adjacent to the meningioma lesion and offers improved contrast differentiation, and may allow for differentiating between intraaxial and extraaxial meningioma lesions. Typical appearance of meningioma is an exraaxial mass with well-defined borders. Homogeneous contrast enhancement is usual, however, areas of calcification or central necrosis may not enhance.

While incidental detection of meningiomas is not uncommon, affected patients may present with various symptoms depending on lesion location. Observation with vigilant neuroimaging may be an option for incidentally discovered and asymptomatic meningiomas [22-24]. Nevertheless, surgery plays a major role in management particularly when patients suffer from symptoms related to mass effect from large meningiomas located at surgically accessible locations. From the neurosurgical standpoint, Simpson described 5 grades of meningioma removal in 1957 and reported an association between aggressiveness of meningioma resection and subsequent tumor recurrences [25,26]. Despite considerable advances in neurosurgery, complete surgical removal of meningiomas may not be achievable in some cases particularly when tumors are seated at critical locations in intricate association with vital neurovascular structures [27-33]. While surgery remains to be a principal management modality for meningiomas, tumor recurrences are not uncommon even after complete surgical resection and cognitive or emotional problems including anxiety or depressive symptoms may develop after resection [23,32-36]. In this context, a multimodality management approach including less agressive surgery followed by adjuvant irradiation has been suggested as a viable therapeutic strategy for patients suffering from symptoms of mass effect in an attempt to improve the toxicity profile of treatment [28,37-41].

Stereotactic irradiation in the form of Stereotactic Radiosurgery (SRS), Fractionated Stereotactic Radiotherapy (FSRT), or Stereotactic Body Radiation Therapy (SBRT) has emerged as a viable therapeutic option for various intracranial and extracranial malign and benign conditions with encouraging treatment outcomes [42-59]. In the context of meningiomas, there has been accumulating experience on the utility of SRS and FSRT as a complementary or primary management for meningiomas [17,26,44,54,60-88].

Rationale for SRS

Enhanced killing of malignant cells may be achieved by high-precision radiosurgery techniques which preclude active tumor repopulation with delivery of limited treatment fractions of high fractional doses, providing effective tumoricidal activity through DNA injury along with induction of apoptosis and vascular endothelial damage [89-93]. Several converging, highly focused radiation beams are used for accurate targeting of intracranial lesions with SRS under excellent patient immobilization and image guidance. Multiple converging beams result in a tumoricidal dose of radiation at the target whilst sparing critical surrounding structures with steep dose gradients. Effectivity of high fraction doses may not be explained solely by the classical 4 Rs of radiotherapy which are repair, repopulation, redistribution and reoxygenation. Mechanism of tumoricidal activity include DNA injury along with induction of apoptosis and vascular endothelial damage which may be accompanied by other contributing factors currently under active investigation [93,94]. Meningiomas may be regarded as late responding tissue thus requiring high biologically effective doses for effective radiotherapy, which render SRS an appealing treatment modality. Typically higher biologically doses achieved with radiosurgery compared to conventionally fractionated radiotherapy may result in higher rates of tumor control with excellent critical organ sparing through steep dose gradients around the target. From the standpoint of patient convenience, radiosurgery may confer improved patient compliance with its typically condensed radiation treatment schedule achieving shortening of overall radiotherapy course and recovery as an outpatient procedure. With widespread adoption of innovative technologies improving treatment precision with decreased costs, radiosurgery started to serve as an affordable and viable radiotherapeutic strategy comprising an indispensable part of both neurosurgery and radiation oncology practice [95-97].

Decision making for treatment of meningiomas with radiosurgery should be made after multidisciplinary evaluation of patients based on lesion size, lesion location and proximity to critical neurovascular structures, symptomatology, patients’ comorbidities, patient preferences, treatment availability and accessibility. Radiosurgery in the form of SRS may be judiciously used for management of well-circumscribed,
small meningioma lesions with a diameter of < 3 cm and volume of < 10-15 cc located at a ≥ 2-3 mm distance away from the optic apparatus while FSRT may offer a viable radiosurgical option with an improved toxicity profile for management of larger meningioma lesions located at critical locations [98-100]. Considering the dose constraint of 8-10 Gy for the optic apparatus in the setting of single-fraction radiosurgery, FSRT may be well-suited for treatment of meningioma lesions abutting or in the vicinity of the optic apparatus. The rationale behind FSRT is to exploit the advantage of fractionation by means of repair and repopulation of normal tissues with potential for improved critical organ sparing whilst maintaining high-precision radiation delivery through excellent patient immobilization under image guidance with contemporary radiosurgical techniques.

Outcomes of Radiosurgery for WHO Grade I Benign Meningioma

Overall, studies of radiosurgery in the form of SRS and FSRT for meningioma consistently suggest improved local control rates both in the primary and salvage treatment setting [17, 26, 44, 54, 60-88, 96-100, 101-105] (Figure 1a and Figure 1b).

Treatment planning for radiosurgery warrants precise target localization. To achieve this goal, imaging with both CT and MR is used for radiosurgery treatment planning. Fusion of CT and MRI allows for improved definition of target and critical organs. Target volume for single fraction radiosurgery typically consists of the contrast enhancing lesion on MRI while an additional margin of 1-2 mm may be used for FSRT under stereotactic immobilization and image guidance.

Critical organs may include the brainstem, optic apparatus, cochlea, and other eloquent brain regions depending on location of the meningioma lesion. While establishing strict dose constraints for radiosurgery may be considered challenging due to the rapid dose fall-off and relatively small irradiated volumes, optic apparatus and brainstem doses below the range of 8-12 Gy may be preferred in single fraction radiosurgery treatments to minimize the risk of radiation induced complications [106,107].

Several factors including the lesion size and volume, proximity to surrounding critical organs and details of prior radiotherapy treatments should be considered in determination of the prescription dose for radiosurgery, however, single fraction doses in the range of 10 to 18 Gy have been typically used for SRS of benign meningiomas [101]. A minimum peripheral tumor dose of ≤ 10 Gy has been associated with higher risk of failure when compared to a dose of ≥ 12 Gy in a study by Ganz, et al. using Gamma Knife radiosurgery for meningiomas [102].

In a study of 188 patients with benign or presumed benign meningioma treated with surgery or SRS alone, Pollock, et al. reported equivalent 7-year progression free survival (PFS) of 95% and 96% for SRS and Simpson grade I surgery, respectively [97]. Nevertheless, tumor control was better with SRS in the setting of less extensive surgery, and SRS was suggested as the primary management modality for meningiomas not amenable to Simpson grade I surgery [97].

In a study of 972 patients with 1045 intracranial meningiomas treated during a 18-year period, Kondziolka, et al. reported an overall control rate of 93% and a 10-year local tumor control rate of 91% for benign meningiomas [103]. Actuarial rates of tumor control was 97%, 87.2%, and 87.2% at 5, 10, and 15 years, respectively [103].
Kessel, et al. recently reported treatment outcomes of patients with meningiomas receiving high-precision radiotherapy as SRS, FSRT, or intensity-modulated radiation therapy [104]. At a median follow-up of 7.2 years, overall survival (OS) rate for the 147 patients with low grade meningiomas was 97%, 85%, and 64% at 3, 10, and 15 years, respectively [104]. Local control rate was 91%, 87%, and 86% at 3, 5, and 10 years, respectively. Long term toxicity was low with excellent local control [104].

A systematic review and metaanalysis by Pinzi, et al. reported an estimated 5-year disease control rate of 87% to 100% and a 10-year disease control rate of 67% to 100% at 10 years with SRS for WHO grade I meningiomas [105]. Progression free survival (PFS) rates at 3, 5, and 10 years were 91.3% to 100%, 78% to 98.9%, and 53.1% to 97.2%, respectively [105]. Overall symptom control and toxicity rates were 92.3% and 8.1%, respectively [105].

### Outcomes of Radiosurgery for WHO Grade II-III Meningiomas

Although studies of radiosurgery typically focused on management of WHO grade I benign meningiomas, radiosurgery has also been utilized for WHO grade II and III meningiomas [103,105,104,108-113].

Due to an increased risk of local recurrence, higher prescription doses than single fraction radiosurgery doses may be required for radiosurgical management of WHO grade II-III meningiomas. A study by Sethi, et al. assessing dose-response relationships for meningioma radiosurgery revealed that treatment dose had a significant effect on local control of meningiomas [103]. Out of the total 108 meningioma lesions treated with Gamma Knife radiosurgery, 20 lesions were WHO grade II-III meningiomas and radiosurgery dose was found to be the strongest determinant of local failure for high grade meningiomas. Authors suggested dose escalation beyond 16 Gy to improve local control of WHO grade II-III meningiomas [103].

In this context, given the probability of differential responses to radiosurgery for meningiomas with different WHO grades, delivery of higher radiosurgery doses may be considered for achieving improved local control for WHO grade II-III meningiomas [103,114].

In the study by Kondziolka, et al. evaluating radiosurgery as definitive treatment modality for meningioma management, tumor control rate was 50% and 17% for WHO grade II and III meningiomas, respectively [105].

The study by Kessel, et al. assessing long-term results of high-precision radiotherapy for meningiomas including 43 high-grade meningioma patients with 40 WHO grade II and 3 WHO grade III meningiomas, local control rate was 67% and 55% at 3 and 5 years, respectively for patients with atypical meningioma while survival rate was 91%, 62%, and 50% at 3, 10, and 15 years, respectively [106].

In the study by Aboukais, et al. assessing the utility of radiosurgery for WHO grade II meningiomas, 27 patients were treated using a radiosurgery dose in the range of 12 to 21 Gy (mean 15.2 Gy) [111]. At a mean follow-up of 56.4 months, actuarial local control rates for all patients were 75%, 52%, and 40% at 1, 2 and 3 years, respectively. The authors concluded that radiosurgery may be considered for management of WHO grade II meningiomas [111].

Choi, et al. evaluated Cyberknife SRS for management of 25 patients with WHO grade II meningiomas [112]. Using a median marginal dose of 22 Gy (range: 16-30 Gy) delivered in 1 to 4 fractions (median 1 fraction), actuarial local control rates for all patients were 94%, 94%, and 74% at 1, 2, and 3 years, respectively [112].

In a comprehensive literature review, Ding, et al., assessed the utility of radiosurgery for WHO grade II-III meningiomas based on 19 radiosurgery series [113]. Median margin dose was 14-21 Gy. Typical margin dose was 16-20 Gy and 18-20 Gy for WHO grade II and WHO grade III meningiomas, respectively. Progression free survival (PFS) was in the range of 25% to 83% (median 59%) for WHO grade II tumors and 0% to 72% (median 13%) for WHO grade III tumors. Median complication rate after radiosurgery was 8% [113].

Overall, accumulating data suggest a potential role for radiosurgery in the management of WHO grade II-III meningiomas despite the need for further supporting evidence.

### Conclusion and Future Directions

Meningiomas are the most common intracranial benign tumors accounting for approximately one third of all diagnosed intracranial neoplasms. Although the majority of meningiomas are WHO Grade I with a typically indolent natural history, they may cause significant patient suffering depending on their location. The literature is short of prospective, randomized controlled studies to dictate treatment algorithms. In this context, decision making for treatment is based primarily on mostly retrospective data. While surgery remains to be a major therapeutic modality, radiosurgery in the form of SRS and FSRT has emerged as a viable treatment strategy for meningioma management. In this context, there is growing body of evidence supporting the role of radiosurgery as a complementary or definitive treatment modality for management of meningiomas. Lesions located at eloquent brain regions in vicinity of critical neurovascular structures may be judiciously treated using radiosurgery to avoid the risks of surgical complications. In some cases, it may be feasible to utilize a combined modality approach including debulking surgery to relieve the mass effect followed by
radiosurgery to improve local disease control. Molecular characterization and gene expressing for meningiomas is currently under active investigation to shed light on potential role of systemic therapies for management.

In conclusion, radiosurgery offers a viable and non-invasive therapeutic strategy for management of meningiomas. Ever-increasing improvements in technology and advances in neuroimaging, radiosurgery techniques, equipment, treatment planning and delivery systems has rendered radiosurgery an attractive treatment modality with growing utilization.

References


